Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a top innovative stock recommended by Wall Street analysts. H.C. Wainwright upgraded its rating to Buy with a price target of $25 after the removal of a clinical hold on the MAGNITUDE-2 study. The company aims to treat transthyretin amyloidosis, a currently incurable disease.

The updated study protocol for Intellia Therapeutics now targets enrollment of around 60 patients, up from the initial 50, focusing on risk mitigation and data comprehension improvements. H.C. Wainwright noted that safety incidents triggering the hold were rare, with less than 0.5% of patients experiencing Grade 4/5 liver issues.

Intellia Therapeutics is a biotech company leading in CRISPR-Cas9 gene-editing tech for cutting-edge treatments. While it shows investment potential, other AI stocks may offer higher returns. For insights on undervalued AI stocks with growth potential, check out a free report on the best short-term AI stock.

For more stock insights, explore the 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds. No promotional content, just facts. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted